Invenra has launched its T-Body™ trispecific antibody platform, a next-generation technology designed to direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs, the company recently announced.

According to a release, the T-Body platform expands on the company’s capabilities to address complex therapeutic targets with enhanced developability.

“Trispecific antibodies represent a major leap forward in therapeutic design, and our T-Body platform offers a unique approach to unlock their potential,” Invera CEO and Chairman Roland Green, Ph.D., said in a statement. “By integrating proprietary CH3 domains, streamlining purification, and achieving strong expression yields, we’re empowering partners to rapidly discover and advance a new class of multispecific therapeutics.”

The biotech company will highlight the T-Body platform at the 21st Annual PEGS Boston conference this week.

Additionally, Invenra announced its collaboration partner, Exelixis, Inc., has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors.